Sanofi (SNY)

44.68
0.33 0.74
NYSE : Health Technology
Prev Close 44.35
Open 44.55
Day Low/High 44.32 / 44.84
52 Wk Low/High 37.43 / 50.04
Volume 975.78K
Avg Volume 1.65M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 109.20B
EPS 1.70
P/E Ratio 23.35
Div & Yield 1.20 (2.92%)

Latest News

What To Do When You Can't Afford Your Chronic Disease Medication

What To Do When You Can't Afford Your Chronic Disease Medication

When Out-of-Pockets get too high, there are many programs to help, whether or not you have insurance

Keeping Women In STEM Careers: Looking To Data For Answers

Keeping Women In STEM Careers: Looking To Data For Answers

BRIDGEWATER, N.J.

Sanofi Aims To Topple The Flu As It Marks National Seniors Day With A Guinness World Record Attempt

Sanofi Aims To Topple The Flu As It Marks National Seniors Day With A Guinness World Record Attempt

Influenza has a significant human and economic impact due to the burden of illness and high number of hospitalizations.

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.

Sanofi US Named To Working Mother 2018 "100 Best Companies" List

Sanofi US Named To Working Mother 2018 "100 Best Companies" List

BRIDGEWATER, N.J.

National Meningitis Association Urges Parents To Get Their Teens The 16 Vaccine To Help Protect Against Meningococcal Meningitis

National Meningitis Association Urges Parents To Get Their Teens The 16 Vaccine To Help Protect Against Meningococcal Meningitis

Vaccination is the best defense against meningococcal disease, yet more than half of U.S. teens have missed the Centers for Disease Control and Prevention's recommended second dose of MenACWY at age 16(1)

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Q2 2018 Performance Positions Sanofi For New Growth Phase

Q2 2018 Performance Positions Sanofi For New Growth Phase

PARIS, July 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Nearly 70 million doses to be manufactured this season

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

Endocrinologists and Adults with Type 1 Diabetes Struggle to Keep Blood Sugar within Recommended Range Yet Remain Hopeful and Optimistic About the Future of Disease Management

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against Tuberculosis, the world's leading infectious disease killer

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

- Company invests €66 million in Chengdu, Sichuan province, China

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Three-quarters of employers are worried about the impact of unmanaged chronic disease Two-thirds (66%) of Canadian employees would consent to receive personalized information based on their own benefits claims...

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

FDA Accepts For Review Supplemental Biologics License Application For 0.5 ML Dose Of Fluzone® Quadrivalent (Influenza Vaccine) In Children 6-35 Months Of Age

- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

The Philippine government says Sanofi knew that the vaccine should not have been given to people who have never had dengue fever.

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

The charges were related to an interest-rate problem.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

TheStreet Quant Rating: B (Buy)